1
Atlas.new
Shares tags: ai
AI Tool
Isomorphic Labs Review
Isomorphic Labs is an AI-driven drug discovery company that uses AI to design new medicines by predicting and generating protein shapes and sequences.
1Isomorphic Labs was spun out of DeepMind in 2021 as an Alphabet company.
2The company secured $600 million in Series B funding in March 2025, valuing it at $3.5 billion.
3In May 2024, Isomorphic Labs jointly released AlphaFold 3 with Google DeepMind, enabling modeling of all life's molecules.
4Strategic collaborations were announced with Eli Lilly and Company and Novartis AG in January 2024, and Johnson & Johnson in January 2026.
⚡
Isomorphic Labs at a Glance
</>Embed "Featured on Stork" Badge▼
<a href="https://www.stork.ai/en/isomorphic-labs" target="_blank" rel="noopener noreferrer"><img src="https://www.stork.ai/api/badge/isomorphic-labs?style=dark" alt="Isomorphic Labs - Featured on Stork.ai" height="36" /></a>
[](https://www.stork.ai/en/isomorphic-labs)
overview
What is Isomorphic Labs?
Isomorphic Labs is an AI-driven drug discovery tool developed by Alphabet that enables pharmaceutical companies and researchers to design novel medicines by predicting and generating protein shapes and sequences. It leverages advanced AI to accelerate the entire drug discovery process, aiming to solve all diseases. Spun out of DeepMind in 2021, Isomorphic Labs employs an AI-first approach to reimagine drug discovery, utilizing a unified AI drug design engine. This engine is built on models capable of operating across multiple therapeutic areas and drug modalities, conducting extensive experimental work "in silico" to explore new chemical spaces and tackle previously intractable targets. The company's technology builds upon the foundational AlphaFold breakthroughs, extending capabilities to predict 3D protein structures and their interactions with other molecules with high accuracy.
quick facts
Quick Facts
| Attribute | Value |
|---|---|
| Developer | Alphabet (spun out of DeepMind) |
| Business Model | Freemium |
| Pricing | Freemium |
| Platforms | Web, API (No) |
| API Available | No |
| Founded | 2021 |
| Funding | Series B, $600 million (March 2025), valued at $3.5 billion |
features
Key Features of Isomorphic Labs
Isomorphic Labs provides a suite of AI-driven capabilities designed to accelerate and enhance the drug discovery process, moving beyond traditional experimental methods.
- 1Uses AI to design new medicines by predicting and generating protein shapes and sequences.
- 2Models complex biological phenomena to design novel molecules with specific properties.
- 3Predicts how drugs will perform and interact with biological systems with high accuracy.
- 4Accelerates the drug discovery pipeline by significantly reducing reliance on wet lab experiments.
- 5Identifies new binding pockets on target proteins using only amino acid sequences.
- 6Develops new drug candidates across multiple therapeutic areas and modalities, including oncology and immunology.
- 7Leverages AlphaFold 3 technology for unprecedented accuracy in modeling structures and interactions of all life's molecules.
- 8Features a Drug Design Engine that reportedly doubled AlphaFold 3's performance on a protein-ligand structure prediction generalization benchmark (February 2026).
use cases
Who Should Use Isomorphic Labs?
Isomorphic Labs is primarily designed for entities and professionals engaged in advanced pharmaceutical research and development, seeking to leverage AI for novel drug discovery.
- 1Pharmaceutical companies: For accelerating drug discovery pipelines, exploring new chemical spaces, and designing novel molecules for various therapeutic areas.
- 2Biomedical companies: To model complex biological phenomena, predict drug performance, and identify new therapeutic targets more efficiently.
- 3Drug discovery experts and computational chemists: For identifying new binding pockets on target proteins and developing new drug candidates with enhanced precision.
- 4Medicinal chemists: To design new drug candidates with specific properties, moving beyond traditional screening methods.
- 5Researchers in biology, chemistry, and medicine: For leveraging advanced AI in understanding molecular interactions and accelerating fundamental research into disease mechanisms.
pricing
Isomorphic Labs Pricing & Plans
Isomorphic Labs operates on a freemium model. Specific details regarding pricing tiers, feature limitations for the free tier, or enterprise-level costs are not publicly disclosed. The company primarily engages in strategic collaborations with pharmaceutical partners, such as Eli Lilly and Company, Novartis AG, and Johnson & Johnson, which likely involve custom agreements, milestone payments, and royalties rather than standardized subscription plans.
competitors
Isomorphic Labs vs Competitors
Isomorphic Labs operates within a competitive landscape of AI-driven drug discovery companies, each offering distinct approaches to leveraging artificial intelligence for therapeutic development.
1
Generate Biomedicines↗
Generate Biomedicines uses a generative AI platform to design novel protein therapeutics from scratch, focusing on a diverse range of therapeutic modalities.
Similar to Isomorphic Labs, Generate Biomedicines focuses on de novo protein design for drug discovery. Their platform emphasizes generating a broader spectrum of therapeutic modalities, whereas Isomorphic Labs explicitly mentions predicting and generating protein shapes and sequences. Pricing is likely enterprise-based, contrasting with Isomorphic Labs' stated freemium model.
2
Xaira Therapeutics↗
Xaira Therapeutics integrates cutting-edge AI research, including technologies like RFdiffusion, with therapeutic development to design novel proteins and antibodies for complex biological challenges.
Like Isomorphic Labs, Xaira Therapeutics leverages advanced AI for protein and antibody design in drug discovery. Xaira appears to have a strong focus on integrating academic AI breakthroughs directly into therapeutic development, potentially offering a broader range of AI models for novel protein and antibody generation.
3
Latent Labs↗
Latent Labs is building generative AI models for de novo protein design, with a focus on creating entirely new therapeutic molecules like antibodies and enzymes to make biology more programmable.
Latent Labs directly competes with Isomorphic Labs in the de novo protein design space, aiming to generate entirely new therapeutic molecules. Their approach emphasizes a predominantly digital workflow with wet lab validation, aligning with Isomorphic's AI-first strategy for drug discovery.
4
DenovAI↗
DenovAI offers an AI-driven platform, AlphaDesign, capable of creating new, functional synthetic proteins entirely de novo without requiring training on evolutionary data or using known protein templates.
DenovAI is a direct competitor to Isomorphic Labs, both aiming to design novel proteins from scratch using AI. DenovAI highlights its ability to generate synthetic proteins without evolutionary templates, potentially offering a distinct approach to sequence and structure generation compared to Isomorphic Labs' methods.
5
ProteinQure↗
ProteinQure specializes in the AI-driven design of novel exotic peptides with broad therapeutic applications, leveraging its ProteinStudio™ computational platform for de novo peptide design and tissue-specific delivery.
ProteinQure, through its ProteinStudio™ platform, directly competes with Isomorphic Labs in AI-driven protein/peptide design for drug discovery. Its unique focus on exotic peptides and clinical-stage development for targeted delivery differentiates its therapeutic application, while Isomorphic Labs focuses more broadly on protein shapes and sequences.
❓
Frequently Asked Questions
+What is Isomorphic Labs?
Isomorphic Labs is an AI-driven drug discovery tool developed by Alphabet that enables pharmaceutical companies and researchers to design novel medicines by predicting and generating protein shapes and sequences. It leverages advanced AI to accelerate the entire drug discovery process, aiming to solve all diseases.
+Is Isomorphic Labs free?
Isomorphic Labs operates on a freemium model. While a free tier is indicated, specific details regarding its features or limitations are not publicly available. The company primarily engages in strategic collaborations with pharmaceutical partners, which involve custom agreements.
+What are the main features of Isomorphic Labs?
Key features include using AI to design new medicines, predicting and generating protein shapes and sequences, modeling complex biological phenomena, predicting drug performance, accelerating drug discovery by reducing wet lab reliance, identifying new binding pockets, and developing new drug candidates across multiple therapeutic areas and modalities. It leverages AlphaFold 3 technology and its own advanced Drug Design Engine.
+Who should use Isomorphic Labs?
Isomorphic Labs is intended for pharmaceutical companies, biomedical companies, drug discovery experts, computational chemists, medicinal chemists, and researchers in biology, chemistry, and medicine who seek to leverage advanced AI for accelerating drug discovery, designing novel molecules, and understanding complex biological interactions.
+How does Isomorphic Labs compare to alternatives?
Isomorphic Labs differentiates itself through its Alphabet backing, DeepMind pedigree, and direct evolution from AlphaFold technology, focusing on a unified AI drug design engine for broad therapeutic applications. Competitors like Generate Biomedicines, Xaira Therapeutics, Latent Labs, DenovAI, and ProteinQure also utilize AI for de novo protein or peptide design, with some focusing on specific modalities, integration of academic research, or unique generative approaches without evolutionary data.